Skip to content
Movie Casting Call
Author:
BeyondSpring, Inc.
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
June 2, 2026
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
May 18, 2026
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
April 22, 2026
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
March 30, 2026
BeyondSpring Files 2025 Annual Report on Form 10-K
March 25, 2026
BeyondSpring Reports 2025 Year-End Financial Results
March 25, 2026